NO883146L - Antiinflamatorisk aktive arylderivater og fremgangsmaate for deres fremstilling. - Google Patents

Antiinflamatorisk aktive arylderivater og fremgangsmaate for deres fremstilling.

Info

Publication number: NO883146L
Authority: NO; Norway
Prior art keywords: formula; compound; methyl; enyl; prop
Prior art date: 1987-07-15

Application number

NO88883146A

Other languages

English (en)

Norwegian (no)

Other versions

NO883146D0 (no

Inventor

John Anthony Salmon

William Paul Jackson

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-07-15

Filing date

1988-07-14

Publication date

1989-01-16

1987-07-15 Priority claimed from GB878716640A external-priority patent/GB8716640D0/en

1988-02-03 Priority claimed from GB888802378A external-priority patent/GB8802378D0/en

1988-03-16 Priority claimed from GB888806278A external-priority patent/GB8806278D0/en

1988-07-14 Application filed by Wellcome Found filed Critical Wellcome Found

1988-07-14 Publication of NO883146D0 publication Critical patent/NO883146D0/no

1989-01-16 Publication of NO883146L publication Critical patent/NO883146L/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 66
238000000034 method Methods 0.000 title claims abstract description 29
150000001875 compounds Chemical class 0.000 claims abstract description 133
150000003839 salts Chemical class 0.000 claims abstract description 56
239000001257 hydrogen Substances 0.000 claims abstract description 22
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 22
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 21
125000001424 substituent group Chemical group 0.000 claims abstract description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 12
150000002431 hydrogen Chemical class 0.000 claims abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
229910052736 halogen Inorganic materials 0.000 claims abstract description 4
125000005843 halogen group Chemical group 0.000 claims abstract description 4
150000002367 halogens Chemical class 0.000 claims abstract description 4
230000008569 process Effects 0.000 claims abstract description 4
125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 84
-1 (E)-N-[1-methyl-3-[3-(4-1-butyl-phenoxy)phenyl]prop-2-enyl]-acetohydroxamic acid Chemical compound 0.000 claims description 30
230000000694 effects Effects 0.000 claims description 24
229960001171 acetohydroxamic acid Drugs 0.000 claims description 20
239000003795 chemical substances by application Substances 0.000 claims description 14
RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 11
125000006239 protecting group Chemical group 0.000 claims description 11
238000011321 prophylaxis Methods 0.000 claims description 10
239000000463 material Substances 0.000 claims description 8
230000001225 therapeutic effect Effects 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
LRPRRGWLXUCVFQ-VOTSOKGWSA-N n-[(e)-4-[3-(4-bromophenoxy)phenyl]but-3-en-2-yl]-n-hydroxyacetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=CC(Br)=CC=2)=C1 LRPRRGWLXUCVFQ-VOTSOKGWSA-N 0.000 claims description 5
230000002685 pulmonary effect Effects 0.000 claims description 5
LWCWFBHLGMHSQM-VOTSOKGWSA-N n-[(e)-4-[3-(4-chlorophenoxy)phenyl]but-3-en-2-yl]-n-hydroxyacetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=CC(Cl)=CC=2)=C1 LWCWFBHLGMHSQM-VOTSOKGWSA-N 0.000 claims description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
230000032683 aging Effects 0.000 claims description 3
239000000924 antiasthmatic agent Substances 0.000 claims description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
FQCSTFXKBOVEEL-MDZDMXLPSA-N n-hydroxy-n-[(e)-4-[3-(4-methylphenoxy)phenyl]but-3-en-2-yl]acetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=CC(C)=CC=2)=C1 FQCSTFXKBOVEEL-MDZDMXLPSA-N 0.000 claims description 3
HFIKWZBHPKVFGX-MDZDMXLPSA-N n-hydroxy-n-[(e)-4-[3-[3-(trifluoromethyl)phenoxy]phenyl]but-3-en-2-yl]acetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=C(C=CC=2)C(F)(F)F)=C1 HFIKWZBHPKVFGX-MDZDMXLPSA-N 0.000 claims description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
230000001088 anti-asthma Effects 0.000 claims description 2
239000003153 chemical reaction reagent Substances 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
230000008635 plant growth Effects 0.000 claims description 2
230000001105 regulatory effect Effects 0.000 claims description 2
229910052727 yttrium Inorganic materials 0.000 claims description 2
125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
230000000202 analgesic effect Effects 0.000 claims 1
230000002744 anti-aggregatory effect Effects 0.000 claims 1
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
230000001754 anti-pyretic effect Effects 0.000 claims 1
230000002006 anti-spasmogenic effect Effects 0.000 claims 1
239000000043 antiallergic agent Substances 0.000 claims 1
239000002221 antipyretic Substances 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
239000011737 fluorine Substances 0.000 claims 1
WAIJNNLGTHPVND-VOTSOKGWSA-N n-[(e)-4-[3-(2,4-difluorophenoxy)phenyl]but-3-en-2-yl]-n-hydroxyacetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C(=CC(F)=CC=2)F)=C1 WAIJNNLGTHPVND-VOTSOKGWSA-N 0.000 claims 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
239000008194 pharmaceutical composition Substances 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 108
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
239000004480 active ingredient Substances 0.000 description 45
239000000047 product Substances 0.000 description 43
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 25
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 25
229920006395 saturated elastomer Polymers 0.000 description 23
239000000243 solution Substances 0.000 description 22
239000000843 powder Substances 0.000 description 20
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
239000003208 petroleum Substances 0.000 description 17
239000002253 acid Substances 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
239000011780 sodium chloride Substances 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
239000002585 base Substances 0.000 description 13
102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 12
101710156627 Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 12
239000000284 extract Substances 0.000 description 12
239000003921 oil Substances 0.000 description 12
235000019198 oils Nutrition 0.000 description 11
238000011282 treatment Methods 0.000 description 11
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
241000196324 Embryophyta Species 0.000 description 9
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 9
229910000027 potassium carbonate Inorganic materials 0.000 description 9
230000009467 reduction Effects 0.000 description 9
239000011734 sodium Substances 0.000 description 9
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 9
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
230000036961 partial effect Effects 0.000 description 8
235000011181 potassium carbonates Nutrition 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
239000000739 antihistaminic agent Substances 0.000 description 7
208000010668 atopic eczema Diseases 0.000 description 7
239000007788 liquid Substances 0.000 description 7
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 7
239000002245 particle Substances 0.000 description 7
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 6
230000001387 anti-histamine Effects 0.000 description 6
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
208000006673 asthma Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000001816 cooling Methods 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
239000012346 acetyl chloride Substances 0.000 description 5
230000000172 allergic effect Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000008213 purified water Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000003826 tablet Substances 0.000 description 5
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
FZCDOAKFNUYYNN-ZHACJKMWSA-N (e)-4-(3-phenoxyphenyl)but-3-en-2-ol Chemical compound CC(O)\C=C\C1=CC=CC(OC=2C=CC=CC=2)=C1 FZCDOAKFNUYYNN-ZHACJKMWSA-N 0.000 description 4
HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
102000003820 Lipoxygenases Human genes 0.000 description 4
108090000128 Lipoxygenases Proteins 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
206010006451 bronchitis Diseases 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
235000019439 ethyl acetate Nutrition 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000005984 hydrogenation reaction Methods 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
ZLIVOFMPDUIULQ-VAWYXSNFSA-N n-hydroxy-n-[(e)-4-(3-phenoxyphenyl)but-3-en-2-yl]acetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=CC=CC=2)=C1 ZLIVOFMPDUIULQ-VAWYXSNFSA-N 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 3
XGLVDUUYFKXKPL-UHFFFAOYSA-N 2-(2-methoxyethoxy)-n,n-bis[2-(2-methoxyethoxy)ethyl]ethanamine Chemical compound COCCOCCN(CCOCCOC)CCOCCOC XGLVDUUYFKXKPL-UHFFFAOYSA-N 0.000 description 3
229960000549 4-dimethylaminophenol Drugs 0.000 description 3
229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 3
229940122142 Lipoxygenase inhibitor Drugs 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
229940114079 arachidonic acid Drugs 0.000 description 3
235000021342 arachidonic acid Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000006196 drop Substances 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
150000004820 halides Chemical class 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
208000002551 irritable bowel syndrome Diseases 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
YXCVPGVZGOKPII-VOTSOKGWSA-N n-[(e)-4-[3-(4-fluorophenoxy)phenyl]but-3-en-2-yl]-n-hydroxyacetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=CC(F)=CC=2)=C1 YXCVPGVZGOKPII-VOTSOKGWSA-N 0.000 description 3
239000002798 polar solvent Substances 0.000 description 3
239000003380 propellant Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
229940085605 saccharin sodium Drugs 0.000 description 3
238000000926 separation method Methods 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
UOWIYNWMROWVDG-UHFFFAOYSA-N 1-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(C)=O UOWIYNWMROWVDG-UHFFFAOYSA-N 0.000 description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
206010027654 Allergic conditions Diseases 0.000 description 2
239000004342 Benzoyl peroxide Substances 0.000 description 2
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
206010007522 Cardiac asthma Diseases 0.000 description 2
241000723353 Chrysanthemum Species 0.000 description 2
244000166102 Eucalyptus leucoxylon Species 0.000 description 2
235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000004166 Lanolin Substances 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
235000019502 Orange oil Nutrition 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000004327 Paroxysmal Dyspnea Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000005903 acid hydrolysis reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
210000005091 airway smooth muscle Anatomy 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
239000003637 basic solution Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
235000019400 benzoyl peroxide Nutrition 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
229940082500 cetostearyl alcohol Drugs 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
229940089960 chloroacetate Drugs 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000012010 growth Effects 0.000 description 2
UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
208000028774 intestinal disease Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019388 lanolin Nutrition 0.000 description 2
229940039717 lanolin Drugs 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 2
FGIGQQUEFBIMSL-VOTSOKGWSA-N n-[(e)-4-[3-(3,5-dichlorophenoxy)phenyl]but-3-en-2-yl]-n-hydroxyacetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=C(Cl)C=C(Cl)C=2)=C1 FGIGQQUEFBIMSL-VOTSOKGWSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000010502 orange oil Substances 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229940068977 polysorbate 20 Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
238000007493 shaping process Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229940035044 sorbitan monolaurate Drugs 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
230000003033 spasmogenic effect Effects 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
230000000707 stereoselective effect Effects 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
229940029284 trichlorofluoromethane Drugs 0.000 description 2
COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
HGGYYKJKWSXKPT-XDHOZWIPSA-N (E)-2-methyl-3-(4-methylphenyl)-2-pyridin-2-yl-5-pyrrolidin-1-ylpent-3-enoic acid Chemical compound N1(CCCC1)C/C=C(\C1=CC=C(C=C1)C)/C(C(=O)O)(C)C1=NC=CC=C1 HGGYYKJKWSXKPT-XDHOZWIPSA-N 0.000 description 1
KZNWHSVHYRGQOC-UHFFFAOYSA-N 1-(dibromomethyl)-3-(4-fluorophenoxy)benzene Chemical compound C1=CC(F)=CC=C1OC1=CC=CC(C(Br)Br)=C1 KZNWHSVHYRGQOC-UHFFFAOYSA-N 0.000 description 1
SCRYDQQUKDZQRS-UHFFFAOYSA-N 1-bromo-3-(4-chlorophenoxy)benzene Chemical compound C1=CC(Cl)=CC=C1OC1=CC=CC(Br)=C1 SCRYDQQUKDZQRS-UHFFFAOYSA-N 0.000 description 1
WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 1
MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
APVQRVSBMIDSFS-UHFFFAOYSA-N 1-fluoro-4-(3-methylphenoxy)benzene Chemical compound CC1=CC=CC(OC=2C=CC(F)=CC=2)=C1 APVQRVSBMIDSFS-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
NIONDZDPPYHYKY-UHFFFAOYSA-N 2-hexenoic acid Chemical compound CCCC=CC(O)=O NIONDZDPPYHYKY-UHFFFAOYSA-N 0.000 description 1
VUGCBIWQHSRQBZ-UHFFFAOYSA-N 2-methylbut-3-yn-2-amine Chemical compound CC(C)(N)C#C VUGCBIWQHSRQBZ-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
MYQFRCYBOOWGJQ-UHFFFAOYSA-N 3-(4-chlorophenoxy)benzaldehyde Chemical compound C1=CC(Cl)=CC=C1OC1=CC=CC(C=O)=C1 MYQFRCYBOOWGJQ-UHFFFAOYSA-N 0.000 description 1
HTBZPEDBMOXWID-UHFFFAOYSA-N 3-(4-fluorophenoxy)benzaldehyde Chemical compound C1=CC(F)=CC=C1OC1=CC=CC(C=O)=C1 HTBZPEDBMOXWID-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
KUERBWLVQJAKIS-UHFFFAOYSA-N 3-hydroxy-1h-imidazol-2-one Chemical compound ON1C=CNC1=O KUERBWLVQJAKIS-UHFFFAOYSA-N 0.000 description 1
MRLGCTNJRREZHZ-UHFFFAOYSA-N 3-phenoxybenzaldehyde Chemical compound O=CC1=CC=CC(OC=2C=CC=CC=2)=C1 MRLGCTNJRREZHZ-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
ISBUYSPRIJRBKX-UHFFFAOYSA-N 5-methyl-2-(2-naphthalen-2-yloxyethyl)-4h-pyrazol-3-one Chemical compound O=C1CC(C)=NN1CCOC1=CC=C(C=CC=C2)C2=C1 ISBUYSPRIJRBKX-UHFFFAOYSA-N 0.000 description 1
235000004507 Abies alba Nutrition 0.000 description 1
241000191291 Abies alba Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000218999 Begoniaceae Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
101100443238 Caenorhabditis elegans dif-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
235000007516 Chrysanthemum Nutrition 0.000 description 1
235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
244000276331 Citrus maxima Species 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
244000115658 Dahlia pinnata Species 0.000 description 1
235000012040 Dahlia pinnata Nutrition 0.000 description 1
240000006497 Dianthus caryophyllus Species 0.000 description 1
235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
241000400611 Eucalyptus deanei Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
101100295738 Gallus gallus COR3 gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018634 Gouty Arthritis Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
235000012308 Tagetes Nutrition 0.000 description 1
241000736851 Tagetes Species 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000004450 alkenylene group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
150000007860 aryl ester derivatives Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000007765 cera alba Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
229940106681 chloroacetic acid Drugs 0.000 description 1
125000004965 chloroalkyl group Chemical group 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000006310 cycloalkyl amino group Chemical group 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
230000027950 fever generation Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
DFUXHKDPVJEPOX-UHFFFAOYSA-N hydroxycarbamoyl acetate Chemical compound CC(=O)OC(=O)NO DFUXHKDPVJEPOX-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000010659 intrinsic asthma Diseases 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
239000011981 lindlar catalyst Substances 0.000 description 1
239000000865 liniment Substances 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000003595 mist Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
OGVPVEBIPIJKEJ-UHFFFAOYSA-N n-(4-phenylbut-3-en-2-ylidene)hydroxylamine Chemical compound ON=C(C)C=CC1=CC=CC=C1 OGVPVEBIPIJKEJ-UHFFFAOYSA-N 0.000 description 1
DQXZIFYMWROPLE-MDZDMXLPSA-N n-[(e)-4-[3-(4-tert-butylphenoxy)phenyl]but-3-en-2-yl]-n-hydroxyacetamide Chemical compound CC(=O)N(O)C(C)\C=C\C1=CC=CC(OC=2C=CC(=CC=2)C(C)(C)C)=C1 DQXZIFYMWROPLE-MDZDMXLPSA-N 0.000 description 1
CEUDWZXMLMKPNN-SOFGYWHQSA-N n-hydroxy-n-[(e)-3-(3-phenoxyphenyl)prop-2-enyl]acetamide Chemical compound CC(=O)N(O)C\C=C\C1=CC=CC(OC=2C=CC=CC=2)=C1 CEUDWZXMLMKPNN-SOFGYWHQSA-N 0.000 description 1
229950011492 nafazatrom Drugs 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
229940088417 precipitated calcium carbonate Drugs 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001047 pyretic effect Effects 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
125000005551 pyridylene group Chemical group 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000009758 senescence Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
AGOSGCWATIJZHQ-UHFFFAOYSA-N tert-butyl [(2-methylpropan-2-yl)oxycarbonylamino] carbonate Chemical compound CC(C)(C)OC(=O)NOC(=O)OC(C)(C)C AGOSGCWATIJZHQ-UHFFFAOYSA-N 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000005556 thienylene group Chemical group 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
229960001128 triprolidine Drugs 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
239000005418 vegetable material Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
- A01N37/28—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof containing the group; Thio analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Agronomy & Crop Science (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Pest Control & Pesticides (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Neurology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO88883146A 1987-07-15 1988-07-14 Antiinflamatorisk aktive arylderivater og fremgangsmaate for deres fremstilling. NO883146L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB878716640A GB8716640D0 (en)	1987-07-15	1987-07-15	Aryl derivatives
GB888802378A GB8802378D0 (en)	1988-02-03	1988-02-03	New aryl derivatives
GB888806278A GB8806278D0 (en)	1988-03-16	1988-03-16	New aryl derivatives

Publications (2)

Publication Number	Publication Date
NO883146D0 NO883146D0 (no)	1988-07-14
NO883146L true NO883146L (no)	1989-01-16

Family

ID=27263507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO88883146A NO883146L (no)	1987-07-15	1988-07-14	Antiinflamatorisk aktive arylderivater og fremgangsmaate for deres fremstilling.

Country Status (18)

Country	Link
US (1)	US4988733A (de)
EP (1)	EP0299761B1 (de)
JP (1)	JPS6445344A (de)
KR (1)	KR890001966A (de)
AT (1)	ATE70530T1 (de)
AU (1)	AU603468B2 (de)
DE (1)	DE3866981D1 (de)
DK (1)	DK392788A (de)
ES (1)	ES2051854T3 (de)
FI (1)	FI883355A7 (de)
GR (1)	GR3003393T3 (de)
HU (1)	HU203076B (de)
IL (1)	IL87105A0 (de)
MC (1)	MC1959A1 (de)
NO (1)	NO883146L (de)
NZ (1)	NZ225408A (de)
PL (1)	PL154186B1 (de)
PT (1)	PT87987B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0288553A (ja) *	1988-07-14	1990-03-28	Wellcome Found Ltd:The	抗炎症性アリール誘導体
AU624896B2 (en) *	1989-02-03	1992-06-25	Wellcome Foundation Limited, The	Anti-inflammatory aryl derivatives
US5476873A (en) *	1990-07-25	1995-12-19	Abbott Laboratories	Acetylene derivatives having lipoxygenase inhibitory activity
ES2095325T3 (es) *	1990-07-25	1997-02-16	Abbott Lab	Derivados de acetileno con una actividad de inhibicion de la lipoxigenasa.
US5234933A (en) *	1991-10-31	1993-08-10	Board Of Governors Of Wayne State University And Vanderbilt University	Cyclic hydroxamic acids
US5169854A (en) *	1992-02-26	1992-12-08	Abbott Laboratories	N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5187192A (en) *	1992-03-13	1993-02-16	Abbott Laboratories	Cyclobutyl derivatives having lipoxygenase inhibitory activity
ES2141162T3 (es) *	1992-06-30	2000-03-16	Us Health	Metodo para producir materiales de barrera con proteccion contra virus.
GB9215921D0 (en) *	1992-07-27	1992-09-09	Wellcome Found	Anti-inflammatory compounds
AU5016793A (en) *	1992-08-20	1994-03-15	Cytomed, Inc	Dual functional anti-inflammatory and immunosuppressive agents
GB9308652D0 (en) *	1993-04-27	1993-06-09	Wellcome Found	Anti-inflammatory compounds
ES2247604T3 (es) *	1995-06-12	2006-03-01	G.D. SEARLE & CO.	Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
AR029916A1 (es) *	2000-05-05	2003-07-23	Smithkline Beecham Corp	N-formil-n-hidroxi-ariloxi alquilaminas y metodos para tratar infecciones bacterianas
AR028075A1 (es) *	2000-05-05	2003-04-23	Smithkline Beecham Corp	Inhibidores de la peptido-desformilasa
US20040034024A1 (en) *	2001-05-04	2004-02-19	Aubart Kelly M	Peptide deformylase inhibitors
AU2002322720B2 (en)	2001-07-25	2008-11-13	Raptor Pharmaceutical Inc.	Compositions and methods for modulating blood-brain barrier transport
CA2789262C (en)	2005-04-28	2016-10-04	Proteus Digital Health, Inc.	Pharma-informatics system
EP2063905B1 (de)	2006-09-18	2014-07-30	Raptor Pharmaceutical Inc	Behandlungen von lebererkrankungen durch verabreichung von konjugaten aus rezeptor-assoziierten proteinen
GB0624187D0 (en) *	2006-12-04	2007-01-10	Jackson William P	HDAC inhibitors
TR201908314T4 (tr)	2009-02-20	2019-06-21	2 Bbb Medicines B V	Glutatyon bazlı ilaç dağıtım sistemi.
KR101909711B1 (ko)	2009-05-06	2018-12-19	라보라토리 스킨 케어, 인크.	활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en)	2010-09-29	2012-03-29	Andrea Bourdelais	Ladder-Frame Polyether Conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3686733T2 (de) *	1985-03-16	1993-02-11	Wellcome Found	Aryl-derivate.
IE59397B1 (en) *	1985-03-16	1994-02-23	Wellcome Found	New aryl derivatives
US4608390A (en) *	1985-04-26	1986-08-26	Abbott Laboratories	Lipoxygenase inhibiting compounds
GB8718212D0 (en) *	1987-07-31	1987-09-09	Angus Fire Armour Ltd	Lining tubular objects

1988
- 1988-07-12 PL PL1988273728A patent/PL154186B1/pl unknown
- 1988-07-14 JP JP63176198A patent/JPS6445344A/ja active Pending
- 1988-07-14 FI FI883355A patent/FI883355A7/fi not_active Application Discontinuation
- 1988-07-14 EP EP88306446A patent/EP0299761B1/de not_active Expired - Lifetime
- 1988-07-14 DE DE8888306446T patent/DE3866981D1/de not_active Expired - Fee Related
- 1988-07-14 PT PT87987A patent/PT87987B/pt not_active IP Right Cessation
- 1988-07-14 US US07/219,096 patent/US4988733A/en not_active Expired - Fee Related
- 1988-07-14 NZ NZ225408A patent/NZ225408A/xx unknown
- 1988-07-14 DK DK392788A patent/DK392788A/da not_active Application Discontinuation
- 1988-07-14 KR KR1019880008745A patent/KR890001966A/ko not_active Withdrawn
- 1988-07-14 NO NO88883146A patent/NO883146L/no unknown
- 1988-07-14 HU HU883683A patent/HU203076B/hu unknown
- 1988-07-14 AT AT88306446T patent/ATE70530T1/de not_active IP Right Cessation
- 1988-07-14 ES ES88306446T patent/ES2051854T3/es not_active Expired - Lifetime
- 1988-07-14 AU AU19068/88A patent/AU603468B2/en not_active Ceased
- 1988-07-14 IL IL87105A patent/IL87105A0/xx unknown
- 1988-07-14 MC MC881991A patent/MC1959A1/fr unknown
1991
- 1991-12-19 GR GR91401878T patent/GR3003393T3/el unknown

Also Published As

Publication number	Publication date
IL87105A0 (en)	1988-12-30
EP0299761B1 (de)	1991-12-18
AU1906888A (en)	1989-01-19
EP0299761A1 (de)	1989-01-18
GR3003393T3 (en)	1993-02-17
DK392788D0 (da)	1988-07-14
PL273728A1 (en)	1989-04-03
PT87987A (pt)	1989-06-30
FI883355A0 (fi)	1988-07-14
PL154186B1 (en)	1991-07-31
MC1959A1 (fr)	1989-06-30
AU603468B2 (en)	1990-11-15
HUT48572A (en)	1989-06-28
JPS6445344A (en)	1989-02-17
NO883146D0 (no)	1988-07-14
ES2051854T3 (es)	1994-07-01
PT87987B (pt)	1995-03-01
DK392788A (da)	1989-01-16
HU203076B (en)	1991-05-28
DE3866981D1 (de)	1992-01-30
FI883355A7 (fi)	1989-01-16
US4988733A (en)	1991-01-29
KR890001966A (ko)	1989-04-07
NZ225408A (en)	1991-09-25
ATE70530T1 (de)	1992-01-15

Publication	Publication Date	Title
NO883146L (no)	1989-01-16	Antiinflamatorisk aktive arylderivater og fremgangsmaate for deres fremstilling.
DE3686733T2 (de)	1993-02-11	Aryl-derivate.
US4738986A (en)	1988-04-19	N-(3-phenoxycinnamyl)acetohydroxamic acid
DE69215108T2 (de)	1997-03-20	Phenylalkansäurederivat, seine herstellung und die trennung seiner optischen isomere
JPH09503771A (ja)	1997-04-15	治療剤
US5036157A (en)	1991-07-30	Aryl derivatives
US5110831A (en)	1992-05-05	Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
WO1987004152A1 (en)	1987-07-16	New aryl derivatives
DD202714A5 (de)	1983-09-28	Verfahren zur herstellung 3-substituierter indolylacrylsaeurederivate
JP3857429B2 (ja)	2006-12-13	含硫黄抗真菌剤
US4977188A (en)	1990-12-11	Method of treating inflammation
EP0351214A1 (de)	1990-01-17	Entzündungshemmende Arylderivate
HUT71556A (en)	1995-12-28	Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl-1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives, pharmaceutical compns. contg. them and process to prepare the said compds.
JPS6084284A (ja)	1985-05-13	抗真菌性トリアゾ−ル誘導体
US4624964A (en)	1986-11-25	Aryl oxo-alkynoates as 5-lipoxygenase inhibitors
NO180534B (no)	1997-01-27	Nonatetraensyrederivat, farmasöytisk preparat inneholdende dette, og anvendelser av derivatet
CS274432B2 (en)	1991-04-11	Method of hydroxamic acid's aryl derivatives preparation
MC2105A1 (fr)	1991-03-11	Derives de tetrahydronaphtalene
GB2202532A (en)	1988-09-28	4-benzylthiophene(or furan)-2-sulfonamides as antiglaucoma agents
JP3857428B2 (ja)	2006-12-13	抗真菌剤
EP0066518B1 (de)	1986-06-11	Verbindungen und Methoden zur Behandlung von Depressionen
KR910003637B1 (ko)	1991-06-07	히드록삼산 아릴 유도체의 제조방법
FR2462426A1 (fr)	1981-02-13	Nouveau derive de la 2-(1-naphtyl)piperidine, sa preparation et son application comme medicament
HUT53615A (en)	1990-11-28	Process for producing thioformamide derivataives and pharmaceutical compositions comprising same
JP3805905B2 (ja)	2006-08-09	芳香族抗真菌剤